Anti-Obesity Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2034

Anti-Obesity Drugs Market Summary

Overview

• The global anti-obesity drugs market was valued at USD 45.8 billion in 2025 and is projected to reach USD 148.6 billion by 2034.
• The market is expected to expand at a CAGR of 14.0% during the forecast period 2026-2034, supported by the rising global prevalence of obesity and overweight, the commercial ascent of dual GIP/GLP-1 and emerging triple agonist therapies, expanding indications into cardiovascular risk reduction and obstructive sleep apnea, and continued pipeline investment in less-frequent-dosing and oral formulations.
• By drug class, the dual/triple agonist segment dominated the anti-obesity drugs market with a 48% share in 2025.
• By route of administration, the subcutaneous/injectable segment dominated the anti-obesity drugs market with an 88% share in 2025, while the oral segment represented the fastest-growing route of administration.
• By indication, the chronic weight management (obesity/overweight) segment dominated the anti-obesity drugs market with a 72% share in 2025.
• By distribution channel, the retail pharmacy segment dominated the anti-obesity drugs market with a 54% share in 2025, while online and telehealth pharmacy channels represented the fastest-growing distribution channel.
• North America accounted for the largest share of the anti-obesity drugs market at 62% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Anti-obesity drugs are pharmacological agents used to treat obesity and overweight, typically in conjunction with a reduced-calorie diet and increased physical activity, delivered via subcutaneous injection or oral administration. The scope encompasses single GLP-1 receptor agonists, including Novo Nordisk's Wegovy (semaglutide) and Saxenda (liraglutide); dual and triple agonists, including Eli Lilly's Zepbound (tirzepatide), a dual GIP/GLP-1 receptor agonist, and pipeline candidates such as Eli Lilly's retatrutide and Boehringer Ingelheim and Zealand Pharma's survodutide; GLP-1/amylin combinations, including Novo Nordisk's investigational CagriSema; melanocortin-4 receptor (MC4R) agonists, including Rhythm Pharmaceuticals' Imcivree (setmelanotide) for rare genetic obesity syndromes; non-incretin combination oral drugs, including Currax Pharmaceuticals' Qsymia (phentermine-topiramate) and Contrave (naltrexone-bupropion); lipase inhibitors, including orlistat; and growth hormone-releasing factor analogs, including Theratechnologies' Egrifta (tesamorelin). The market spans chronic weight management, cardiometabolic risk reduction, obstructive sleep apnea, and rare genetic obesity indications.

Anti-Obesity Drugs Market Key Growth Drivers

• Rising global prevalence of obesity and overweight, with the World Health Organization estimating that nearly 1 in 8 adults worldwide live with obesity, sustaining broad-based demand for pharmacological weight management.
• Commercial ascent of dual GIP/GLP-1 and emerging triple agonist therapies, exemplified by Eli Lilly's Zepbound generating USD 22.9 billion in 2025 sales, a 188.7% increase over the prior year, and overtaking Novo Nordisk's Wegovy as the leading obesity drug by revenue.
• Expanding regulatory indications beyond weight loss alone into cardiovascular risk reduction and obstructive sleep apnea, exemplified by Wegovy's cardiovascular risk reduction approval and Zepbound's November 2025 expanded indication for moderate-to-severe obstructive sleep apnea in adults with obesity.
• Continued pipeline investment in less-frequent-dosing and oral formulations, including Amgen's monthly-dosing MariTide and Eli Lilly's investigational oral GLP-1 agonist orforglipron, expanding patient convenience and access.
• Growing direct-to-consumer and telehealth distribution channels that expand patient access and awareness of anti-obesity drug therapy beyond traditional clinical referral pathways.
• Rising manufacturing capacity investment by leading manufacturers, including Eli Lilly's announced USD 6.5 billion Houston manufacturing facility, addressing sustained global demand and prior supply constraints.
• Sustained investment in next-generation multi-receptor agonist mechanisms, including GLP-1/amylin combinations and GLP-1/GIP/glucagon triple agonists, that demonstrate weight loss efficacy approaching bariatric surgery outcomes.

Key Companies in Anti-Obesity Drugs Market

The leading participants in the anti-obesity drugs market include the following:

• Novo Nordisk A/S
• Eli Lilly and Company
• Amgen Inc.
• Roche Holding AG
• Boehringer Ingelheim International GmbH
• Rhythm Pharmaceuticals, Inc.
• Viking Therapeutics, Inc.
• Structure Therapeutics Inc.
• Zealand Pharma A/S
• Currax Pharmaceuticals LLC

Factors Contributing to the Growth of the Anti-Obesity Drugs Market

Market Drivers

Rising Global Prevalence of Obesity and Overweight

The foundational driver of the anti-obesity drugs market is the rising global prevalence of obesity and overweight, with the World Health Organization estimating that nearly 1 in 8 adults worldwide are living with obesity. Obesity is strongly associated with type 2 diabetes, cardiovascular disease, obstructive sleep apnea, and numerous other comorbidities, positioning effective pharmacological weight management as a growing public health priority rather than an elective intervention. As the global prevalence of obesity and overweight continues to rise, driven by urbanization, dietary shifts, and sedentary lifestyles, the population eligible for pharmacological weight management expands correspondingly, sustaining demand across the market's full range of drug classes throughout the forecast period.

Commercial Ascent of Dual GIP/GLP-1 and Triple Agonist Therapies

The commercial ascent of dual GIP/GLP-1 and emerging triple agonist therapies represents the defining structural development in the anti-obesity drugs market. Eli Lilly's Zepbound (tirzepatide) generated USD 22.9 billion in sales in 2025, a 188.7% increase over the prior year, overtaking Novo Nordisk's Wegovy, which reached USD 18.6 billion in 2025 sales, as the leading obesity drug by revenue. This shift reflects head-to-head clinical evidence, including the SURMOUNT-5 trial reported in December 2024, in which Zepbound achieved 20.2% average weight loss compared to 13.7% for Wegovy over 72 weeks. As Eli Lilly and Novo Nordisk continue to invest in next-generation multi-receptor agonist candidates, including Eli Lilly's triple agonist retatrutide and Novo Nordisk's amylin-combination CagriSema, dual and triple agonist mechanisms are expected to sustain their position as the market's largest and most dynamic drug class across the forecast period.

Market Restraints

The anti-obesity drugs market faces several interrelated restraints that temper its growth. The high cost of branded GLP-1, dual agonist, and multi-receptor agonist therapies, combined with variable and inconsistent insurance coverage for weight management indications specifically, constrains broader adoption and creates substantial patient out-of-pocket cost burden. Patient adherence and persistence challenges affect the market broadly, with real-world data indicating that a meaningful share of patients discontinue anti-obesity drug therapy within the first year of treatment, often related to gastrointestinal side effects, cost, or treatment fatigue. The proliferation of compounded and unauthorized copies of branded semaglutide and tirzepatide products has introduced safety concerns and created commercial disruption for originator manufacturers, complicating market dynamics during periods of branded product supply constraint. Upcoming government drug pricing negotiations for Novo Nordisk's semaglutide, effective in the United States in 2027, create commercial uncertainty for pricing and revenue projections. The requirement for continued long-term therapy to sustain weight loss outcomes, given the well-documented pattern of weight regain following treatment discontinuation, raises questions about long-term treatment adherence, cost sustainability, and health system budget impact. Together, these factors moderate the pace of adoption and require manufacturers to demonstrate affordability, supply reliability, and long-term adherence support to sustain growth.

Anti-Obesity Drugs Market Segment Analysis

The global anti-obesity drugs market by drug class (single GLP-1 receptor agonists, dual/triple agonists, GLP-1/amylin combinations, melanocortin-4 receptor (MC4R) agonists, non-incretin combination oral drugs, lipase inhibitors, and others), by route of administration (subcutaneous/injectable and oral), by indication (chronic weight management [obesity/overweight], obesity with cardiometabolic risk reduction, obstructive sleep apnea with obesity, rare genetic obesity syndromes, and others), by distribution channel (retail pharmacy, hospital pharmacy, and online/telehealth pharmacy), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Drug Class

Dominant Subsegment: Dual/Triple Agonists.

The dual/triple agonist category is expected to dominate the market. The segment accounted for a 48% share of the anti-obesity drugs market in 2025. This class, led by Eli Lilly's Zepbound (tirzepatide), a dual GIP/GLP-1 receptor agonist, is the leading drug class because it has demonstrated superior weight loss efficacy relative to single GLP-1 receptor agonist therapy in head-to-head clinical trials, translating directly into commercial share gains, with Zepbound's 2025 sales growth of 188.7% substantially outpacing the growth of single-agonist competitors. The dominance of the segment reflects the scale of Eli Lilly's commercial investment, the depth of clinical evidence supporting superior efficacy, and the continued advancement of triple agonist candidates such as retatrutide that extend the mechanism further. While single GLP-1 receptor agonists, led by Novo Nordisk's Wegovy, remain a substantial and clinically important category, and GLP-1/amylin combinations and MC4R agonists serve important complementary and niche roles respectively, the demonstrated efficacy advantage and commercial momentum of dual and triple agonist mechanisms sustain the leadership of the segment across the forecast period.

By Route of Administration

Dominant Subsegment: Subcutaneous/Injectable.

The subcutaneous/injectable category is expected to dominate the market. The subcutaneous/injectable segment accounted for an 88% share of the anti-obesity drugs market in 2025. Injectable therapy, including both leading commercial products, Wegovy and Zepbound, is the leading route of administration because weekly self-injection remains the standard formulation for the highest-efficacy, highest-revenue anti-obesity drugs currently marketed. The dominance of the segment reflects the continued predominance of injectable delivery among the top-selling branded anti-obesity drugs and the fact that the newly approved oral semaglutide formulation and Eli Lilly's investigational oral orforglipron remain in the earliest stages of commercial rollout or clinical development, respectively. The oral route of administration represented the fastest-growing route in 2025, driven by the late-2025 FDA approval of an oral semaglutide pill for chronic weight management and the anticipated future launch of orforglipron, and is expected to gain share progressively as additional oral candidates reach the market across the forecast period.

Anti-Obesity Drugs Market Region Analysis

Dominant Region: North America

North America accounted for a 62% share of the global anti-obesity drugs market in 2025, representing the highest regional market share globally. The leadership of the region reflects the concentration of Wegovy and Zepbound commercial revenue in the United States, driven by high obesity prevalence, expanding commercial and government insurance coverage for weight management indications, and the aggressive direct-to-consumer and telehealth commercial strategies both Novo Nordisk and Eli Lilly have built around their franchises. The United States is the largest national market, supported by high healthcare expenditure, the concentration of leading manufacturers, and the depth of FDA regulatory activity extending anti-obesity drug indications into cardiovascular and sleep apnea comorbidities. The concentration of commercial revenue, reimbursement structures, and manufacturer investment reinforce the position of North America as the largest regional market across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region faces a rapidly escalating obesity burden alongside expanding healthcare access and rising disposable income, with China, Japan, and India representing substantial addressable populations for anti-obesity drug therapy. Novo Nordisk launched Wegovy in India in June 2025, marking the drug's first approval in the country both for chronic weight management and for cardiovascular risk reduction, while Eli Lilly's Mounjaro has seen strong early uptake in the Indian market. As regional manufacturing partnerships, government healthcare investment, and rising consumer awareness of pharmacological weight management continue to develop, the region increases its adoption of anti-obesity drugs from a growing base, positioning Asia-Pacific as the fastest-growing regional market across the forecast period.

Regional Commentary

North America

North America leads the market, supported by the concentration of Wegovy and Zepbound commercial revenue, expanding insurance coverage, and aggressive direct-to-consumer commercial strategies. The United States dominates the region through its concentration of manufacturers and its outsized share of global anti-obesity drug revenue.

Europe

Europe is a significant market shaped by national health technology assessment pathways, rising obesity prevalence, and the presence of leading manufacturers including Novo Nordisk, Boehringer Ingelheim, and Zealand Pharma. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, and the region continues to navigate reimbursement negotiations that shape the pace of anti-obesity drug adoption relative to the more commercially permissive United States market.

Asia-Pacific

Asia-Pacific is the fastest-growing region, driven by the scale of the obesity-affected population in China and India, expanding healthcare access, and recent market entries such as Novo Nordisk's 2025 launch of Wegovy in India.

Rest of World

The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as obesity prevalence rises and healthcare access expands, though adoption of advanced, higher-cost drug classes remains concentrated in leading urban centers and private healthcare systems.

Anti-Obesity Drugs Market Competitive Landscape

The global anti-obesity drugs market is classified as Consolidated. Novo Nordisk and Eli Lilly together hold a dominant share of commercial revenue, effectively forming a duopoly at the center of the market, while a broader group of pharmaceutical and biotechnology companies advance differentiated pipeline candidates targeting novel mechanisms, dosing intervals, and administration routes. Competition centers on the breadth and depth of the multi-receptor agonist pipeline, clinical evidence supporting comorbidity-specific indications, manufacturing capacity to meet sustained demand, and the pace of oral and less-frequent-dosing formulation development. The competitive landscape is evaluated across the following dimensions:

• Market concentration: Consolidated, with Novo Nordisk and Eli Lilly together dominating commercial revenue, alongside Amgen, Roche, Boehringer Ingelheim, Rhythm Pharmaceuticals, Viking Therapeutics, Structure Therapeutics, Zealand Pharma, and Currax Pharmaceuticals competing across pipeline and niche established drug classes.
• Leading players: Eli Lilly leads through its Zepbound franchise, having overtaken Novo Nordisk's Wegovy in 2025 commercial revenue and captured a majority of new US patient starts by mid-2025; Novo Nordisk maintains a leading position through Wegovy and its CagriSema and amycretin pipeline; and Rhythm Pharmaceuticals leads the rare genetic obesity niche through Imcivree.
• Geographic reach: Novo Nordisk and Eli Lilly operate global commercial and regulatory organizations, while specialist and pipeline-stage companies including Rhythm Pharmaceuticals, Viking Therapeutics, and Structure Therapeutics maintain more concentrated footprints centered on specific mechanisms and geographies.
• Product portfolio strength: Competitive advantage rests on the breadth across single agonist, dual/triple agonist, and amylin-combination mechanisms, and on the depth of clinical evidence supporting expanded cardiovascular, sleep apnea, and other comorbidity-specific indications.
• Pipeline strength: Development is concentrated in triple agonist candidates, monthly and less-frequent dosing formulations, and oral small-molecule GLP-1 agonists, with Amgen, Viking Therapeutics, Structure Therapeutics, Zealand Pharma, Hanmi Pharmaceutical, Kailera Therapeutics, and Metsera all advancing differentiated late-stage candidates.
• Strategic partnerships: Collaboration spans licensing and co-development agreements for next-generation candidates, exemplified by Boehringer Ingelheim's partnership with Zealand Pharma on survodutide, and manufacturing capacity partnerships addressing sustained global demand.
• M&A activity: Consolidation has shaped the field, exemplified by Roche's acquisition of Carmot Therapeutics to establish an obesity drug pipeline including CT-388 and CT-996, reflecting the broader pattern of larger pharmaceutical companies acquiring specialized obesity drug developers to establish or expand competitive position.
• Innovation focus: Innovation is concentrated in triple agonist mechanisms, GLP-1/amylin combinations, monthly-dosing formulations that reduce injection frequency, and oral small-molecule GLP-1 agonists that eliminate the need for injection.
• Regulatory standing: FDA approval of expanded comorbidity-specific indications, exemplified by Zepbound's November 2025 obstructive sleep apnea approval and Wegovy's cardiovascular risk reduction approval, are decisive competitive credentials that extend prescribing beyond weight loss alone.

Anti-Obesity Drugs Market Recent Developmental Activities

• In November 2025, the FDA approved an expanded indication for Eli Lilly's Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, based on SURMOUNT-OSA trial data. Strategic significance: the approval extended Zepbound's addressable market beyond weight management into a major sleep medicine indication.
• In late 2025, the FDA approved an oral semaglutide formulation for chronic weight management. Strategic significance: the approval introduced the first oral formulation of a leading anti-obesity drug, expanding access beyond injection-tolerant patients.

Anti-Obesity Drugs Market Segmentation

Anti-Obesity Drugs Market Assessment by Drug Class

• Single GLP-1 Receptor Agonists
• Dual/Triple Agonists
• GLP-1/Amylin Combinations
• Melanocortin-4 Receptor (MC4R) Agonists
• Non-Incretin Combination Oral Drugs
• Lipase Inhibitors
• Others

Anti-Obesity Drugs Market Assessment by Route of Administration

• Subcutaneous/Injectable
• Oral

Anti-Obesity Drugs Market Assessment by Indication

• Chronic Weight Management (Obesity/Overweight)
• Obesity with Cardiometabolic Risk Reduction
• Obstructive Sleep Apnea with Obesity
• Rare Genetic Obesity Syndromes
• Others

Anti-Obesity Drugs Market Assessment by Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Online/Telehealth Pharmacy

Anti-Obesity Drugs Market Assessment by Geography

• North America
• United States Anti-Obesity Drugs Market Size in USD million (2023-2034)
• Canada Anti-Obesity Drugs Market Size in USD million (2023-2034)
• Mexico Anti-Obesity Drugs Market Size in USD million (2023-2034)
• Europe
• Germany Anti-Obesity Drugs Market Size in USD million (2023-2034)
• United Kingdom Anti-Obesity Drugs Market Size in USD million (2023-2034)
• France Anti-Obesity Drugs Market Size in USD million (2023-2034)
• Italy Anti-Obesity Drugs Market Size in USD million (2023-2034)
• Spain Anti-Obesity Drugs Market Size in USD million (2023-2034)
• Rest of Europe Anti-Obesity Drugs Market Size in USD million (2023-2034)
• Asia-Pacific
• China Anti-Obesity Drugs Market Size in USD million (2023-2034)
• Japan Anti-Obesity Drugs Market Size in USD million (2023-2034)
• India Anti-Obesity Drugs Market Size in USD million (2023-2034)
• Australia Anti-Obesity Drugs Market Size in USD million (2023-2034)
• South Korea Anti-Obesity Drugs Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Anti-Obesity Drugs Market Size in USD million (2023-2034)
• Rest of the World
• Middle East Anti-Obesity Drugs Market Size in USD million (2023-2034)
• Africa Anti-Obesity Drugs Market Size in USD million (2023-2034)
• South America Anti-Obesity Drugs Market Size in USD million (2023-2034)

Key Takeaways from the Anti-Obesity Drugs Market Report Study

• Market size analysis for the current anti-obesity drugs market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key research, clinical, and commercial developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global anti-obesity drugs market.
• Various opportunities available for competitors in the anti-obesity drugs market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current anti-obesity drugs market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for anti-obesity drugs market growth in the future?

Target audience who can benefit from this anti-obesity drugs market report study

• Anti-obesity drug manufacturers
• Research organizations and consulting companies
• Obesity medicine and endocrinology-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in anti-obesity drugs
• Various end-users who want to know more about the anti-obesity drugs market and the latest research developments in the anti-obesity drugs market.

Frequently Asked Questions

Q1. At what rate is the anti-obesity drugs market expected to grow?

The global anti-obesity drugs market is projected to grow at a compound annual growth rate of 14.0% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the anti-obesity drugs market?

The global anti-obesity drugs market was valued at USD 45.8 billion in 2025 and is projected to reach USD 148.6 billion by 2034.

Q3. Which region dominates the anti-obesity drugs market?

North America dominated the anti-obesity drugs market with a 62% share in 2025, driven by the concentration of Wegovy and Zepbound commercial revenue and expanding insurance coverage. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by the scale of the obesity-affected population in China and India and recent market entries such as the 2025 launch of Wegovy in India.

Q4. What are the key factors driving growth in the anti-obesity drugs market?

The principal drivers are the rising global prevalence of obesity and overweight; the commercial ascent of dual GIP/GLP-1 and emerging triple agonist therapies; expanding regulatory indications into cardiovascular risk reduction and obstructive sleep apnea; continued pipeline investment in less-frequent-dosing and oral formulations; and the growth of direct-to-consumer and telehealth distribution channels.

Q5. Who are the major players in the anti-obesity drugs market?

The market is consolidated and led by Novo Nordisk A/S and Eli Lilly and Company, which together dominate commercial revenue, alongside Amgen Inc., Roche Holding AG, Boehringer Ingelheim, Rhythm Pharmaceuticals, Inc., Viking Therapeutics, Inc., Structure Therapeutics Inc., Zealand Pharma A/S, and Currax Pharmaceuticals LLC.

This product will be delivered within 2 business days.